Hyaluronan-Loaded Liposomal Dexamethasone–Diclofenac Nanoparticles for Local Osteoarthritis Treatment

Autor: Yu-Jen Kuo, Ying-Cheng Chiang, Ming-Cheng Chang, Kuan-Yin Chen, Ping-Fang Chiang, Cheng-Liang Peng
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Neutrophils
Osteoarthritis
Pharmacology
lcsh:Chemistry
chemistry.chemical_compound
Mice
0302 clinical medicine
Oral administration
hemic and lymphatic diseases
Hyaluronic acid
polycyclic compounds
Hyaluronic Acid
lcsh:QH301-705.5
Spectroscopy
Drug Carriers
Molecular Structure
General Medicine
Computer Science Applications
Joint pain
Toxicity
medicine.symptom
liposomal nanoparticle
hormones
hormone substitutes
and hormone antagonists
medicine.drug
circulatory and respiratory physiology
Diclofenac
dexamethasone
Catalysis
Article
Inorganic Chemistry
03 medical and health sciences
medicine
Animals
Humans
Physical and Theoretical Chemistry
Adverse effect
Molecular Biology
Dexamethasone
business.industry
Organic Chemistry
medicine.disease
osteoarthritis
Drug Liberation
Kinetics
030104 developmental biology
chemistry
lcsh:Biology (General)
lcsh:QD1-999
Liposomes
Nanoparticles
business
Leukocyte Elastase
030217 neurology & neurosurgery
Zdroj: International Journal of Molecular Sciences
International Journal of Molecular Sciences, Vol 22, Iss 665, p 665 (2021)
Volume 22
Issue 2
ISSN: 1422-0067
Popis: Osteoarthritis (OA) remains one of the common degenerative joint diseases and a major cause of pain and disability in older adult individuals. Oral administration of non-steroidal anti-inflammatory drugs (NSAIDs) (such as diclofenac, DIC) or intra-articular injected gluco-corticosteroids (such as dexamethasone, DEX) were the conventional treatment strategies for OA to reduce joint pain. Current limitations for both drugs including severe adverse effects with risks of toxicity were noted. The aim of the present study was to generate a novel OA treatment formulation hyaluronic acid (HA)-Liposomal (Lipo)-DIC/DEX to combat joint pain. The formulation was prepared by constructing DIC with DEX-loaded nanostructured lipid carriers Lipo-DIC/DEX mixed with hyaluronic acid (HA) for prolonged OA application. The prepared Lipo-DIC/DEX nanoparticles revealed the size as 103.6 ±
0.3 nm on average, zeta potential as &minus
22.3 ±
4.6 mV, the entrapment efficiency of 90.5 ±
5.6%, and the DIC and DEX content was 22.5 ±
4.1 and 2.5 ±
0.6%, respectively. Evidence indicated that HA-Lipo-DIC/DEX could reach the effective working concentration in 4 h and sustained the drug-releasing time for at least 168 h. No significant toxicities but increased cell numbers were observed when HA-Lipo-DIC/DEX co-cultured with articular chondrocytes cells. Using live-animal In vivo imaging system (IVIS), intra-articular injection of each HA-Lipo-DIC/DEX sufficed to reduce knee joint inflammation in OA mice over a time span of four weeks. Single-dose injection could reduce the inflammation volume down to 77.5 ±
5.1% from initial over that time span. Our results provided the novel drug-releasing formulation with safety and efficiency which could be a promising system for osteoarthritis pain control.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje